Posters

1, 2, and 3 year results for standalone MIGS surgery in open-angle glaucoma with the Hydrus® Microstent from the global SPECTRUM registry

Poster Details

First Author: L.Au UK

Co Author(s):                        

Abstract Details

Purpose:

The SPECTRUM registry is an international, muliticenter data set consisting of real world experience of the Hydrus Microstent (Ivantis, Irvine CA) in an all-comers clinical setting. This is a report of the 12, 24, and 36 month results for the cohort of eyes with open angle glaucoma with no prior filtration surgery treated with standalone Hydrus MIGS surgery from 2014-2017.

Setting:

The SPECTRUM registry is being conducted in 51 clinics located in 17 countries in Europe, North America, South America, the Middle East, and Asia/Pacific Rim. Over 60 surgeons are participating in the registry.

Methods:

Participating surgeons are required to enter data from their Hydrus cases into the data base through a secure web portal. Data includes baseline demographic and ocular status, IOP, medication count, visual field mean deviation, and history of prior glaucoma or ocular surgeries. A follow-up visit was conducted between 1 and 3 months and repeated annually. IOP, medication, and adverse event outcomes are collected. Eyes with open angle glaucoma (POAG, PXG, PDG) with no prior filtration surgery was extracted from the data base.

Results:

427 eyes met the search criteria. Mean age was 70.3±12.1 years. Eyes were 90.3% POAG, 6.8% PXG, and 2.7% PDG; 9.0% were pseudophakic, 32.6% had prior SLT. Glaucoma severity ranged from mild to advanced (VF-MD -8.8±7.9 dB). Baseline IOP and medication count were 20.2±5.9 mmHg and 2.6±1.2. Follow-up was completed in 321 (77.8%), 173 (40.5%) and 70 (16.4%) of eyes at 12, 24 and 36 months. Follow-up IOP was 16.4±4.9, 15.8±4.4 and 15.1±3.8 mmHg at 12, 24 and 36 months (p<0.05 at each time point) and medication count was 1.4±1.4, 1.6±1.4, and 1.4±1.2 (p<0.05 at each time point).

Conclusions:

In a large scale online multicenter global registry, standalone MIGS with the Hydrus microstent significantly reduced IOP and medications through 36 months compared to preoperative levels.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company